An innovation arm of a large health system is responsible for sourcing external facing innovation outside of the health system’s network, and seeks various strategic partnering opportunities with early-stage companies.  With a meaningful appetite for risk, the firm seeks to partner with companies through a combination of in-kind and other co-development resources, with an intention playing the part of “first paying customer.”  The firm aims to engage 10-15 deals on a yearly basis and is currently open to global opportunities.

The firm is most interested in digital health, HCIT, and process transformation opportunities, and will consider medical devices (predominantly of the “wearables” and monitoring types). The firm does not consider therapeutics companies. The firm is open to various indications, but is most interested technologies targeting care administration/operations, cancer, neuroscience, and ALS.  As the firm seeks to be the first paying customer, the firm is very open to the earliest stage digital health technologies, but companies who have yet to close an angel round might be considered too early.

The firm does not have specific company or management team requirements. The firm is actively involved in the growth of their portfolio companies, and leverage their internal resources and network to support their growth and customer traction.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA-based firm with over $2 billion USD under management invests in external venture capital funds, and also has a fund to make direct investments in early stage companies. The firm focuses on investing in startups with some connection to universities who have strong ties with the firm (such as IP developed at the university or R&D being performed there) but also makes some investments into outside startups.  Initial investments are typically made at an early stage, and most are from $250,000-1 million; the firm also makes follow-on investments. The firm invests primarily in the US and also considers opportunities in Canada.

The firm invests in a wide variety of technology sectors; in the life sciences, the fund is focused on diagnostics, medical devices, and innovative areas of digital health.  The firm is opportunistic and will consider life science innovations broadly; areas of high interest include cancer care, AI, machine learning, clinical decision support systems, and imaging.  The firm will consider investing at a very early stage of development.

In addition, the firm has an additional innovation capital program for developing innovative technology in the US Midwest, including resources for incubating and accelerating new life science startups.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A global pharmaceutical company with an established USA-based subsidiary, is interested in forming partnerships with emerging life science and digital health companies that are relevant to the company’s  pharmaceutical pipeline. These partnerships may include in-licensing, global or regional rights, and potentially also equity investments in venture financing rounds. The firm will consider partnerships with emerging companies based anywhere in the world.

The firm is interested in therapeutic assets, with a focus on the respiratory space, and also rare diseases, and cardiovascular care in a hospital setting. In North America, the firm focuses on drugs at Phase II through commercial stages; however the firm will consider opportunities at any stage from academic work onwards.  The firm is also interested in digital health solutions related to its therapeutic business, such as digital products that help with patient adherence or compliance, or which use data in ways that can help the firm understand or identify patient populations in its core areas (particularly rare diseases).

The firm does not have specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A cross-border life science investment firm focuses on the pharmaceutical, medical device, and diagnostics sectors. In addition to investment, the firm is actively involved in supporting their portfolio companies through cross-border partnerships. The firm generally makes investments ranging from $5-30 M, and is currently seeking global opportunities.

For pharmaceuticals, the firm looks at assets ranging from Ph I to marketed with a preference towards post-Phase IIb products, but is open to promising, earlier stage opportunities with strong clinical data. For medical device products, the firm looks at a wide variety of products with a preference for technologies that are soon to be market ready. Sector interests include but are not limited to cardiovascular, surgical, ENT, orthopedics, wound care, robotics, and others. For diagnostics, the firm invests in a broad range of technology including POCT, IVD, and molecular diagnostics but also targets non-conventional and invasive diagnostics (such as IVUS/OCT, breath based, GI, etc…). The firm is also interested in revenue generating companies working in the animal health space.

The firm has no specific management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A multinational pharmaceutical company headquartered in Japan is actively looking globally for opportunities to in-license cutting-edge, early stage therapeutic assets. Sponsored research may also be considered with a focus on Japan-based academic institutions. In addition, the firm is an active investor into Series A raises and invests up to $1M in initial investment, for which the firm considers global opportunities.

The firm’s external R&D is focused on both neurodegenerative and neurodevelopmental diseases including Parkinson’s disease, autism, Rett Syndrome, fragile X, and lysosomal storage diseases. The firm is interested in platform technology and early stage hits/seeds in CNS, orphan disease, and genetically defined platform and asset focused companies with strong emphasis on novel drug discovery platforms. This includes new MOAs such as gene therapy, stem cell therapy, BBB penetrating biologics and monoclonal antibodies acting on new targets. The firm is also interested in later-stage assets (phase III to on the market) in diabetes, immunology, and infectious diseases for the Asia markets.

The firm is looking for assets that would be strategic a fit with its current portfolio. The firm is willing to negotiate regional rights based each therapeutic field. For example, in immunology and neurology, the firm would prefer both US and Asia rights. In diabetes, infectious diseases, and other areas, the firm can request Asia rights only.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A hybrid family office and operating company with USA offices makes investments ranging from approximately $500,000 to $100 million into companies, and due to its funding structure has no requirements for holding period or capital structure. The firm makes investments in the forms of equity, controlling interest, in-licensing, MBO/LBO, growth capital and is also willing to co-invest. The firm is looking for companies located around the globe and makes around 5-15 investments in a given year.

The firm is looking for companies in sectors of Biotech Therapeutics and Diagnostics, Medtech, Digital Health, R&D Services, and Biotech Other. The firm is willing to consider all indications including orphan diseases, though they have some additional interest/experience is areas of Women’s Health, GI, Oncology and Cardiovascular, and Personalized Medicine including Proteomics and Genomics. The firm is most interested in companies that are in Phase II or later, nearing commercialization where the firm is capable of utilizing its operating company to scale up the company’s sales, marketing and distribution. That being said the firm has made earlier stage investments in the past and is open to considering highly innovative and compelling early stage companies. The firm is also interested in companies developing consumables/reagents, service providers, food and nutraceuticals.

The firm looks to work with management teams with experience and grit and generally looks to take a board seat although it is not a requirement. The firm looks to leverage the use of its operating company to assist the company’s sales marketing and distribution efforts as well as providing assistance in operations management.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in China is currently investing from their first USD fund and actively raising for their second USD fund to invest in companies based in USA and Canada. The firm also shifted their paradigm that in the next 5 years, they will have 60% of the fund and portfolio companies from the U.S. The firm focuses on Series A-B deals within the US, Canada, and China and typically invests USD 2-5 million per deal. The firm typically co-invests, but is willing to lead in specific situations.

The firm is opportunistic within the therapeutics and medical technology domains. However, for therapeutics, the firm focuses mostly on assets that are currently in Phase I or Phase II clinical trials. For Medical Devices, they prefer technologies that already have 510k or PMA clearance. Most importantly though, when investing, The firm requires that the technology has strong clinical evidence of efficacy. Strong evidence of efficacy is the most important criteria for the firm when investing in therapeutics and medical technology.

The firm is looking for a management team with a strong history of success as serial entrepreneurs or with strong clinical backgrounds. For investment opportunities without FDA clearance, the firm prefers seeing management teams with prior success in achieving FDA approval or candidates who have strong background from big pharma.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.